Revvity Methyl-4-Phenylpyridinium Acetate, N--, MPP (+), 250uCi (9.25MBq)

250 µCi quantities of Methyl-4-Phenylpyridinium Acetate, N-[Methyl-³H]-, MPP (+), are available for your research. MPP+ is a dopaminergic selective neurotoxin, and has been used to study Parkinsons disease.

We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays.

Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments.

References for NET914:

1. Kristufek, D., Rudorfer, W., Pifl, C. and Huck, S. (2002), Organic cation transporter mRNA and function in the rat superior cervical ganglion. The Journal of Physiology, 543: 117–134.
2. Russ, H., Gliese, M., Sonna, J. et Al. The extraneuronal transport mechanism for noradrenaline (uptake2) avidly transports 1-methyl-4-phenylpyridinium (MPP+). Naunyn-Schmiedebergs Arch Pharmacol (1992) 346: 158.